|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 166.91 USD | -0.11% |
|
-5.66% | +35.53% |
Business description: Jazz Pharmaceuticals plc
Number of employees: 2,800
Sales by Activity: Jazz Pharmaceuticals plc
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Pharmaceutical Products | 2.36B | 3.09B | 3.66B | 3.83B | 4.07B |
Geographical breakdown of sales: Jazz Pharmaceuticals plc
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States | 2.14B | 2.82B | 3.37B | 3.49B | 3.66B |
Europe | 175M | 230M | 240M | 269M | 313M |
Other | 43.82M | 43.84M | 49.36M | 74.98M | 96.14M |
Executive Committee: Jazz Pharmaceuticals plc
| Manager | Title | Age | Since |
|---|---|---|---|
Renée Galá
CEO | Chief Executive Officer | 53 | 2025-08-10 |
Philip Johnson
DFI | Director of Finance/CFO | 60 | 2024-02-29 |
Liz Henderson
CTO | Chief Tech/Sci/R&D Officer | 53 | 2023-07-31 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 58 | 2019-05-28 |
Jeff Macdonald
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: Jazz Pharmaceuticals plc
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Cozadd
CHM | Chairman | 61 | 2019-10-24 |
Seamus Mulligan
BRD | Director/Board Member | 64 | 2012-01-17 |
Rick Winningham
BRD | Director/Board Member | 65 | 2009-12-31 |
Heather McSharry
BRD | Director/Board Member | 63 | 2013-05-01 |
Norbert Riedel
BRD | Director/Board Member | 67 | 2013-05-12 |
Anne O’Riordan
BRD | Director/Board Member | 57 | 2019-02-13 |
Jennifer Cook
BRD | Director/Board Member | 59 | 2020-11-30 |
Mark Smith
BRD | Director/Board Member | 73 | 2020-11-30 |
Patrick Enright
BRD | Director/Board Member | 63 | 2009-06-30 |
Patrick Kennedy
BRD | Director/Board Member | 56 | 2024-02-29 |
Company details: Jazz Pharmaceuticals plc
Group companies: Jazz Pharmaceuticals plc
| Name | Category and Sector |
|---|---|
Jazz Securities DAC
 Jazz Securities DAC Functions as a financing subsidiary/special purpose entity | |
Jazz Securities DAC
Jazz Securities DAC Functions as a financing subsidiary/special purpose entity | |
Jazz Investments II Ltd.
 Jazz Investments II Ltd. Acts as a financing subsidiary/Special purpose entity | |
Jazz Investments II Ltd.
Jazz Investments II Ltd. Acts as a financing subsidiary/Special purpose entity | |
Jazz Financing Holdings Ltd.
 Jazz Financing Holdings Ltd. Functions as an investment holding company |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.11% | -5.66% | +35.20% | +6.14% | 10.15B | |
| -1.85% | -8.14% | +22.25% | +170.70% | 925B | |
| -1.39% | -2.45% | +34.57% | +13.19% | 495B | |
| -0.66% | +0.46% | +29.61% | +39.75% | 407B | |
| -1.18% | +0.26% | +22.23% | +0.60% | 335B | |
| -1.31% | -3.55% | +28.95% | +20.90% | 283B | |
| -0.48% | +2.14% | +18.62% | +27.03% | 257B | |
| -1.35% | -3.57% | -0.47% | -8.32% | 254B | |
| +0.66% | -1.64% | -60.79% | -31.82% | 211B | |
| -1.52% | -1.28% | +22.25% | +19.14% | 186B | |
| Average | -0.58% | -2.52% | +15.24% | +25.73% | 336.4B | |
| Weighted average by Cap. | -0.93% | -3.23% | +18.36% | +56.05% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JAZZ Stock
- Company Jazz Pharmaceuticals plc
Select your edition
All financial news and data tailored to specific country editions
